- Home
- PHAR vs NUVB Comparison
PHAR vs NUVB Comparison
Compare PHAR & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NUVB
- Stock Information
- Founded
- PHAR 1988
- NUVB 2018
- Country
- PHAR Netherlands
- NUVB United States
- Employees
- PHAR N/A
- NUVB N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- NUVB Health Care
- Exchange
- PHAR Nasdaq
- NUVB Nasdaq
- Market Cap
- PHAR 587.5M
- NUVB 679.9M
- IPO Year
- PHAR N/A
- NUVB N/A
- Fundamental
- Price
- PHAR $10.03
- NUVB $2.10
- Analyst Decision
- PHAR Strong Buy
- NUVB Strong Buy
- Analyst Count
- PHAR 3
- NUVB 5
- Target Price
- PHAR $30.00
- NUVB $8.20
- AVG Volume (30 Days)
- PHAR 3.0K
- NUVB 3.2M
- Earning Date
- PHAR 05-08-2025
- NUVB 05-07-2025
- Dividend Yield
- PHAR N/A
- NUVB N/A
- EPS Growth
- PHAR N/A
- NUVB N/A
- EPS
- PHAR N/A
- NUVB N/A
- Revenue
- PHAR $320,708,000.00
- NUVB $10,957,000.00
- Revenue This Year
- PHAR $12.39
- NUVB $75.73
- Revenue Next Year
- PHAR $9.84
- NUVB $440.21
- P/E Ratio
- PHAR N/A
- NUVB N/A
- Revenue Growth
- PHAR 24.13
- NUVB N/A
- 52 Week Low
- PHAR $6.65
- NUVB $1.54
- 52 Week High
- PHAR $11.07
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- PHAR 71.76
- NUVB 50.80
- Support Level
- PHAR $8.60
- NUVB $1.98
- Resistance Level
- PHAR $10.28
- NUVB $2.30
- Average True Range (ATR)
- PHAR 0.30
- NUVB 0.16
- MACD
- PHAR 0.17
- NUVB -0.01
- Stochastic Oscillator
- PHAR 88.79
- NUVB 21.43
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).